Davita (DVA) stock price is $187.13, down 0.09% on the day, as of Oct 19, 2026. It has a market cap of $12.13Bn and a P/E ratio of 14.31, and is classified in the Healthcare Services industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap12.13 Bn
P/E14.31
P/S0.87
Div. Yield0.00
Total Debt (Qtr)10.78 Bn
Revenue Growth (1y) (Qtr)5.17
Add ratio to table…
About
DaVita Inc. is a leading healthcare provider that delivers comprehensive kidney care services to patients worldwide. The company focuses on slowing the progression of chronic kidney disease providing dialysis treatment supporting transplantation and offering integrated care management across the care continuum. DaVita operates dialysis centers provides laboratory services and manages care coordination programs for patients with end stage renal disease and earlier stages of…
DaVita Inc. is a leading healthcare provider that delivers comprehensive kidney care services to patients worldwide. The company focuses on slowing the progression of chronic kidney disease providing dialysis treatment supporting transplantation and offering integrated care management across the care continuum. DaVita operates dialysis centers provides laboratory services and manages care coordination programs for patients with end stage renal disease and earlier stages of kidney disease. DaVita has been operating for more than twenty five years and has built a platform that integrates clinical care with technology and data analytics. The company’s care model emphasizes patient choice and seeks to deliver preventative services that slow disease progression while preparing patients for transplant when appropriate. DaVita’s workforce includes registered nurses licensed practical nurses patient care technicians social workers dietitians biomedical technicians and administrative staff who work together to deliver high quality dialysis services.
DaVita generates revenue primarily from its U. S. dialysis business which provides outpatient hemodialysis peritoneal dialysis hospital inpatient dialysis and related laboratory services to patients with end stage renal disease. The company also earns revenue from its U. S. integrated kidney care segment through care management contracts with health plans and government programs that include shared savings pay for performance and capitation arrangements. International operations contribute revenue by delivering dialysis and administrative services in outpatient centers located outside the United States. Additional income comes from U. S. other ancillary services such as clinical research transplant software and venture investments that support drug development and innovative care solutions. Revenue is sourced from government programs including Medicare Medicare Advantage Medicaid and the Veterans Administration as well as from commercial insurance payors and direct patient payments. In 2025 the U. S. dialysis segment accounted for approximately eighty six percent of consolidated revenues while the remaining revenue came from integrated kidney care international operations and ancillary services. The company’s laboratory operations provide routine testing for dialysis adequacy mineral metabolism and other health indicators supporting clinical decision making. Management services fees are earned based on a percentage of revenues or cash collections from outpatient dialysis centers in which DaVita holds a noncontrolling interest or provides administrative support. Integrated kidney care contracts often include outcomes based payments that reward improvements in hospitalization rates and mortality risk. International operations generate revenue through fee for service dialysis treatments and through administrative agreements that cover staffing supply chain and quality oversight.
The company operates through the following segments: U. S. dialysis U. S. integrated kidney care international operations and U. S. other ancillary services. These segments are defined by the nature of the services they provide rather than by geography and each contributes differently to the company’s overall revenue profile.
U. S. dialysis provides dialysis treatments laboratory testing and management services to patients with end stage renal disease across a network of freestanding outpatient dialysis centers hospital based units and home settings. The segment generates revenue from outpatient hemodialysis peritoneal dialysis hospital inpatient dialysis and laboratory services as well as management fees for centers in which DaVita holds a noncontrolling interest or provides administrative support. As of December 31 2025 the U. S. dialysis segment served approximately two hundred thousand five hundred patients across two thousand six hundred fifty seven outpatient dialysis centers located in forty six states and the District of Columbia. The segment also provided hospital inpatient dialysis services to patients in roughly seven hundred forty hospitals throughout the United States. Home based hemodialysis and peritoneal dialysis programs are supported through training equipment and monitoring provided by registered nurses.
U. S. integrated kidney care delivers care coordination disease management and predictive analytics services to health plan and government program beneficiaries with chronic kidney disease and end stage renal disease. The segment operates under various payment models including shared savings pay for performance and capitation contracts and supports Chronic Special Needs Plans to provide integrated healthcare for eligible patients. As of December 31 2025 the integrated kidney care business managed care for sixty six thousand patients in risk based arrangements and an additional nine thousand four hundred patients in other integrated care arrangements across the United States. The segment works with health plans to design care pathways that include medication management dietary counseling and coordination with transplant centers. Revenue is recognized as services are delivered over contract periods or based on achievement of predefined quality and cost targets.
International operations own manage or provide administrative services to outpatient dialysis centers in fourteen countries outside the United States serving approximately ninety four thousand five hundred patients. The segment offers hemodialysis and peritoneal dialysis treatments and generates revenue from dialysis services laboratory testing and management fees in markets such as Brazil Colombia Malaysia Poland Chile Germany United Kingdom Ecuador Saudi Arabia Panama Portugal China Japan and Singapore. The international footprint consists of five hundred eighty five outpatient dialysis centers spread across fourteen nations. The largest concentrations are in Brazil with one hundred twenty seven centers Colombia with seventy four centers Malaysia with seventy one centers and Poland with sixty four centers. Smaller operations exist in Chile Germany United Kingdom Ecuador Saudi Arabia Panama Portugal China Japan and Singapore. The segment adapts its treatment offerings to local regulatory requirements while maintaining consistent clinical standards.
U. S. other ancillary services include clinical research programs transplant software and venture investment activities that support drug development device innovation and new care delivery models. These businesses earn revenue from study sponsorship fees software licensing transactions and strategic investments in companies focused on digital health pharmaceuticals and medical devices for kidney disease patients. The clinical research organization provides services for retrospective and prospective studies supporting drug and device development for kidney disease. The transplant software business known as MedSleuth connects transplant candidates with centers and care teams to improve matching and post transplant outcomes. The venture group seeks early stage investments in digital health pharmaceuticals and medical devices that align with DaVita’s strategy to expand preventive kidney care.
DaVita holds a leading position in the United States dialysis market where it is one of the two largest providers alongside Fresenius Medical Care. The company has been recognized as an industry leader in the Centers for Medicare & Medicaid Services Quality Incentive Program for eleven consecutive years and in the Five Star Quality Rating System for ten consecutive years. DaVita’s competitive advantages stem from its extensive network of dialysis centers its longstanding relationships with nephrologists and hospitals its ability to offer home based and in center dialysis options and its growing integrated kidney care business that leverages value based payment models to improve outcomes and lower total cost of care. The company also benefits from scale in laboratory services management services and ancillary businesses that support its core dialysis operations. Fresenius Medical Care remains DaVita’s primary competitor in the United States dialysis market with both companies together serving a substantial share of the total end stage renal disease patient population. DaVita’s scale enables it to negotiate favorable terms with suppliers and to invest in clinical quality initiatives that have yielded consistent high scores in government quality programs. The company’s integrated kidney care platform differentiates it from pure play dialysis providers by offering care management that addresses the full spectrum of chronic kidney disease. Additionally DaVita’s focus on home based dialysis options aligns with policy incentives that encourage utilization of peritoneal dialysis and home hemodialysis.
DaVita serves patients with end stage renal disease and earlier stages of chronic kidney disease who receive dialysis treatment and care management services. The company’s customers include federal and state government programs such as Medicare Medicare Advantage Medicaid and the Veterans Administration as well as commercial health plans that provide coverage for dialysis services. DaVita also contracts with hospitals that require inpatient dialysis services and with independent laboratories that need specialized testing for kidney disease patients. While the filing does not disclose individual commercial payer names it notes that no single commercial payor accounts for more than ten percent of U. S. dialysis revenue indicating a diversified payer mix. Medicare remains the largest single payer covering approximately seventy three percent of U. S. dialysis patients while Medicare Advantage plans contribute an additional share that varies by region. Medicaid and managed Medicaid programs account for about seven percent of dialysis revenue and the Veterans Administration provides services to a smaller but important segment of patients. Commercial insurance payors collectively represent roughly thirty two percent of U. S. dialysis patient service revenues with no individual commercial payer exceeding ten percent of the segment’s revenue. This diversified payer base reduces reliance on any single source of reimbursement and supports revenue stability across different economic cycles.
Sectors:Healthcare·TechnologySector rationaleDaVita is primarily a healthcare provider, generating the vast majority of its revenue (86% from U.S. dialysis alone) through clinical services such as hemodialysis, peritoneal dialysis, and laboratory testing for patients with kidney disease. A secondary sector of Technology is justified because the company operates a distinct business line selling transplant software (MedSleuth) via licensing transactions, which is a separate revenue stream from its clinical care delivery.Industries:+1 moreHealthcare ServicesHealthcare ServicesPrimaryDaVita primarily operates a vast network of freestanding outpatient dialysis centers and provides physician practice management and specialty care for patients with end-stage renal disease. Its core revenue is generated from per-procedure dialysis treatments delivered in these outpatient clinic settings.Diagnostic LabsDiagnostic LabsSecondaryThe company operates laboratory services that provide routine testing for dialysis adequacy and mineral metabolism to support clinical decision making, billing for these diagnostic tests.Healthcare ITHealthcare ITSecondaryDaVita sells a proprietary transplant software product called MedSleuth, which connects transplant candidates with care teams to improve matching and outcomes, generating revenue through software licensing.Classified using BQ-MICSCIK: 0000927066
Bull & bear
Investment Thesis
▲ Bull case
DaVita's Integrated Kidney Care business is delivering measurable progress that the market may be underestimating. In the latest results from the CMS Comprehensive Kidney Care Contracting program the company reported year over year improvements across gross savings rates total quality score and high performing status. This performance translated into the highest total aggregate savings of any participant driven by a 4.5% improvement in gross saving rate since the program's inception. The combination of clinical rigor and data driven insights is creating a sustainable model for the future of kidney care that could generate long term value beyond traditional dialysis revenues. Management highlighted that IKC is not only improving clinical outcomes but also lowering hospitalizations and improving patient well being which adds to the societal benefit of the model. The early success of IKC suggests that as value based care expands DaVita could capture a growing share of payments tied to quality and efficiency rather than volume alone. This structural shift may reduce reliance on volatile treatment volumes and provide a more predictable earnings stream over the long term.
The company's disciplined AI strategy is building a foundation that could unlock operational efficiencies and clinical benefits not yet reflected in guidance. DaVita has modernized its data infrastructure by standardizing and integrating high quality data across the enterprise through its proprietary EMR platform. This work provides a differentiated base to power AI applications at scale while the firm actively deploys AI solutions in clinical operational and business use cases. Early tools such as Schedule Hub already show promise in reducing administrative burden and enhancing teammate experience which could translate into lower costs and better patient outcomes over time. Beyond scheduling DaVita is exploring AI driven predictive analytics for patient risk stratification and treatment optimization which may further improve clinical results and reduce waste. The investments made today are expected to compound as the data ecosystem matures providing a durable competitive advantage that is difficult for rivals to replicate. Management emphasized that the long term view is to sustain three% to seven% operating income growth over time through technology enabled efficiencies.
Volume upside is being driven by more durable factors than the market assumes including Fresenius clinic transfers and underlying mortality improvements. Quarter end census benefited from patient transfers related to ongoing clinic closures by Fresenius which management expects to contribute positively to treatment growth over the remainder of the year. Although the mortality benefit observed in the first quarter was modest the company noted it stemmed from underlying trends rather than seasonal flu patterns suggesting some persistence. Management raised full year volume growth guidance from flat to a range of 25 to 50 basis points increase citing half from better underlying performance and half from transfers. The underlying performance component reflects productivity gains and process improvements that could continue to deliver incremental volume without relying on external events. If these internal improvements are sustained the volume base could provide a more resilient platform for earnings growth. The combination of internal efficiency gains and external transfer opportunities creates a diversified source of volume support that reduces downside risk.
ACA enrollment trends are proving more favorable than the company's initial $40 million headwind assumption which could alleviate pressure on revenue per treatment. Management noted that open enrollment is trending toward a slightly favorable outcome relative to prior expectations and that any benefit will be partially offset by a shift toward lower level bronze plans. This dynamic suggests that the net impact on revenue per treatment may be less severe than modeled and could even turn neutral or positive as the year progresses. The company is maintaining its $40 million headwind estimate while acknowledging current trends are better than that figure providing a potential upside surprise. A shift toward lower level plans may increase patient out of pocket spending but could also stimulate greater engagement with preventive care and chronic disease management programs offered by DaVita. Enhanced patient engagement in these programs may improve health outcomes and reduce downstream costs which could offset some of the revenue pressure from lower premium plans. The net effect on profitability remains uncertain but the enrollment environment appears less negative than originally feared.
DaVita's capital allocation strategy demonstrates financial flexibility and commitment to shareholder returns which supports a bullish outlook. The firm repurchased three million shares in the first quarter and an additional two million shares after quarter end including shares bought from Berkshire Hathaway under its repurchase agreement. At the end of the first quarter the leverage ratio stood at 3.34 times consolidated EBITDA well within the target range of 3 to 3.5 times. This balance sheet position gives the company capacity to continue investing in technology and value based care while returning cash to shareholders. Strong free cash flow generation of $140 million in the quarter further underscores the ability to fund growth initiatives without excessive reliance on external financing. The ongoing share repurchase program signals confidence in intrinsic value and provides a buffer against market volatility. Additionally the company's disciplined approach to debt management ensures that interest coverage remains comfortable even if rates rise moderately. Together these factors create a solid foundation for sustained shareholder value creation over the medium to long term.
DaVita's Integrated Kidney Care business is delivering measurable progress that the market may be underestimating. In the latest results from the CMS Comprehensive Kidney Care Contracting program the company reported year over year improvements across gross savings rates total quality score and high performing status. This performance translated into the highest total aggregate savings of any participant driven by a 4.5% improvement in gross saving rate since the program's inception. The combination of clinical rigor and data driven insights is creating a sustainable model for the future of kidney care that could generate long term value beyond traditional dialysis revenues. Management highlighted that IKC is not only improving clinical outcomes but also lowering hospitalizations and improving patient well being which adds to the societal benefit of the model. The early success of IKC suggests that as value based care expands DaVita could capture a growing share of payments tied to quality and efficiency rather than volume alone. This structural shift may reduce reliance on volatile treatment volumes and provide a more predictable earnings stream over the long term.
The company's disciplined AI strategy is building a foundation that could unlock operational efficiencies and clinical benefits not yet reflected in guidance. DaVita has modernized its data infrastructure by standardizing and integrating high quality data across the enterprise through its proprietary EMR platform. This work provides a differentiated base to power AI applications at scale while the firm actively deploys AI solutions in clinical operational and business use cases. Early tools such as Schedule Hub already show promise in reducing administrative burden and enhancing teammate experience which could translate into lower costs and better patient outcomes over time. Beyond scheduling DaVita is exploring AI driven predictive analytics for patient risk stratification and treatment optimization which may further improve clinical results and reduce waste. The investments made today are expected to compound as the data ecosystem matures providing a durable competitive advantage that is difficult for rivals to replicate. Management emphasized that the long term view is to sustain three% to seven% operating income growth over time through technology enabled efficiencies.
Volume upside is being driven by more durable factors than the market assumes including Fresenius clinic transfers and underlying mortality improvements. Quarter end census benefited from patient transfers related to ongoing clinic closures by Fresenius which management expects to contribute positively to treatment growth over the remainder of the year. Although the mortality benefit observed in the first quarter was modest the company noted it stemmed from underlying trends rather than seasonal flu patterns suggesting some persistence. Management raised full year volume growth guidance from flat to a range of 25 to 50 basis points increase citing half from better underlying performance and half from transfers. The underlying performance component reflects productivity gains and process improvements that could continue to deliver incremental volume without relying on external events. If these internal improvements are sustained the volume base could provide a more resilient platform for earnings growth. The combination of internal efficiency gains and external transfer opportunities creates a diversified source of volume support that reduces downside risk.
ACA enrollment trends are proving more favorable than the company's initial $40 million headwind assumption which could alleviate pressure on revenue per treatment. Management noted that open enrollment is trending toward a slightly favorable outcome relative to prior expectations and that any benefit will be partially offset by a shift toward lower level bronze plans. This dynamic suggests that the net impact on revenue per treatment may be less severe than modeled and could even turn neutral or positive as the year progresses. The company is maintaining its $40 million headwind estimate while acknowledging current trends are better than that figure providing a potential upside surprise. A shift toward lower level plans may increase patient out of pocket spending but could also stimulate greater engagement with preventive care and chronic disease management programs offered by DaVita. Enhanced patient engagement in these programs may improve health outcomes and reduce downstream costs which could offset some of the revenue pressure from lower premium plans. The net effect on profitability remains uncertain but the enrollment environment appears less negative than originally feared.
DaVita's capital allocation strategy demonstrates financial flexibility and commitment to shareholder returns which supports a bullish outlook. The firm repurchased three million shares in the first quarter and an additional two million shares after quarter end including shares bought from Berkshire Hathaway under its repurchase agreement. At the end of the first quarter the leverage ratio stood at 3.34 times consolidated EBITDA well within the target range of 3 to 3.5 times. This balance sheet position gives the company capacity to continue investing in technology and value based care while returning cash to shareholders. Strong free cash flow generation of $140 million in the quarter further underscores the ability to fund growth initiatives without excessive reliance on external financing. The ongoing share repurchase program signals confidence in intrinsic value and provides a buffer against market volatility. Additionally the company's disciplined approach to debt management ensures that interest coverage remains comfortable even if rates rise moderately. Together these factors create a solid foundation for sustained shareholder value creation over the medium to long term.
Growth in general and administrative expenses is outpacing revenue growth creating a margin pressure risk that the market may be overlooking. U.S dialysis G&A costs rose $16 million from the seasonally high fourth quarter but showed a year over year increase of $37 million or 13% versus the Q1 FY25. Management acknowledged that the G&A line is growing at a faster rate than revenue yet argued that total cost growth remains within historical ranges. However if the trend continues the dilution of operating leverage could erode the benefits of volume and pricing improvements. The rise in G&A is largely driven by continued investment in technology and infrastructure which may not yield immediate returns. Should these investments fail to produce expected efficiencies the expense base could become a persistent drag on profitability. Investors should monitor whether the company can rein in G&A growth while still pursuing its strategic initiatives.
The volume guidance increase relies heavily on transient factors that may not be sustainable limiting the durability of the upside. Management attributed half of the upward revision to better underlying performance and half to transfers from Fresenius clinic closures which are nonrecurring in nature. The mortality improvement observed in the first quarter was described as modest and not clearly linked to a lasting trend raising questions about its persistence. If these temporary drivers fade the company could revert to flat or negative volume growth undermining the raised guidance. Furthermore the underlying performance component may be partially offset by wage inflation and other cost pressures that could blunt productivity gains. The company's ability to sustain volume growth will depend on its success in attracting and retaining patients in a competitive market where rivals are also pursuing similar strategies. Any slowdown in net patient additions would directly impact treatment volumes and could pressure earnings forecasts.
ACA enrollment dynamics pose a risk to revenue per treatment that could offset any favorable enrollment outcome. While open enrollment is trending better than expected the company warned that more patients selecting lower level bronze plans will increase out of pocket costs and create a modest RPT headwind. This shift toward higher patient cost sharing could pressure profitability especially if the mix change persists throughout the year. The net effect on revenue per treatment remains uncertain and could erode the anticipated benefit from higher enrollment. Additionally lower premium plans may be associated with higher utilization of emergency services and hospitalizations which could increase overall healthcare costs for the patient population. Such cost shifting could ultimately affect DaVita's reimbursement rates if payers respond by tightening budgets or imposing stricter utilization controls. The interaction between enrollment mix and reimbursement dynamics adds a layer of complexity that could surprise investors to the downside.
Regulatory and reimbursement pressures combined with rising interest rates could constrain profitability and limit the company's ability to capitalize on its investments. The administration's focus on fraud waste and abuse although not directly targeting dialysis introduces uncertainty around future billing practices and audit intensity. Additionally debt expense in the first quarter was $145 million and management expects quarterly debt expense to remain similar due to higher share repurchases and higher interest rate expectations. An environment of increasing rates could raise the cost of capital and affect the present value of future cash flows from growth initiatives. Higher borrowing costs may also make it more expensive to finance acquisitions or capital projects which could slow the pace of strategic investments. If the company cannot pass on increased costs to payers margins may compress further especially in a setting where reimbursement growth is already modest. The combination of regulatory scrutiny and financial headwinds creates a challenging backdrop for long term value creation.
Despite upward revisions to operating income and EPS guidance free cash flow expectations have remained static suggesting potential cash conversion challenges. Management noted that free cash flow variability is wider and therefore the guide was not adjusted even as operating income increased. This disconnect could indicate that improvements in profitability are not translating into proportional cash generation possibly due to working capital timing or higher capital expenditures. If free cash flow fails to grow alongside earnings the company may face constraints on debt reduction share repurchases and strategic investments. The static free cash flow outlook also raises questions about the sustainability of the current capital allocation strategy which balances buybacks with reinvestment needs. Should operating cash generation weaken the firm might need to prioritize debt repayment over shareholder returns or delay planned technology upgrades. Such a scenario could limit the upside potential of the growth initiatives that management has highlighted.
Growth in general and administrative expenses is outpacing revenue growth creating a margin pressure risk that the market may be overlooking. U.S dialysis G&A costs rose $16 million from the seasonally high fourth quarter but showed a year over year increase of $37 million or 13% versus the Q1 FY25. Management acknowledged that the G&A line is growing at a faster rate than revenue yet argued that total cost growth remains within historical ranges. However if the trend continues the dilution of operating leverage could erode the benefits of volume and pricing improvements. The rise in G&A is largely driven by continued investment in technology and infrastructure which may not yield immediate returns. Should these investments fail to produce expected efficiencies the expense base could become a persistent drag on profitability. Investors should monitor whether the company can rein in G&A growth while still pursuing its strategic initiatives.
The volume guidance increase relies heavily on transient factors that may not be sustainable limiting the durability of the upside. Management attributed half of the upward revision to better underlying performance and half to transfers from Fresenius clinic closures which are nonrecurring in nature. The mortality improvement observed in the first quarter was described as modest and not clearly linked to a lasting trend raising questions about its persistence. If these temporary drivers fade the company could revert to flat or negative volume growth undermining the raised guidance. Furthermore the underlying performance component may be partially offset by wage inflation and other cost pressures that could blunt productivity gains. The company's ability to sustain volume growth will depend on its success in attracting and retaining patients in a competitive market where rivals are also pursuing similar strategies. Any slowdown in net patient additions would directly impact treatment volumes and could pressure earnings forecasts.
ACA enrollment dynamics pose a risk to revenue per treatment that could offset any favorable enrollment outcome. While open enrollment is trending better than expected the company warned that more patients selecting lower level bronze plans will increase out of pocket costs and create a modest RPT headwind. This shift toward higher patient cost sharing could pressure profitability especially if the mix change persists throughout the year. The net effect on revenue per treatment remains uncertain and could erode the anticipated benefit from higher enrollment. Additionally lower premium plans may be associated with higher utilization of emergency services and hospitalizations which could increase overall healthcare costs for the patient population. Such cost shifting could ultimately affect DaVita's reimbursement rates if payers respond by tightening budgets or imposing stricter utilization controls. The interaction between enrollment mix and reimbursement dynamics adds a layer of complexity that could surprise investors to the downside.
Regulatory and reimbursement pressures combined with rising interest rates could constrain profitability and limit the company's ability to capitalize on its investments. The administration's focus on fraud waste and abuse although not directly targeting dialysis introduces uncertainty around future billing practices and audit intensity. Additionally debt expense in the first quarter was $145 million and management expects quarterly debt expense to remain similar due to higher share repurchases and higher interest rate expectations. An environment of increasing rates could raise the cost of capital and affect the present value of future cash flows from growth initiatives. Higher borrowing costs may also make it more expensive to finance acquisitions or capital projects which could slow the pace of strategic investments. If the company cannot pass on increased costs to payers margins may compress further especially in a setting where reimbursement growth is already modest. The combination of regulatory scrutiny and financial headwinds creates a challenging backdrop for long term value creation.
Despite upward revisions to operating income and EPS guidance free cash flow expectations have remained static suggesting potential cash conversion challenges. Management noted that free cash flow variability is wider and therefore the guide was not adjusted even as operating income increased. This disconnect could indicate that improvements in profitability are not translating into proportional cash generation possibly due to working capital timing or higher capital expenditures. If free cash flow fails to grow alongside earnings the company may face constraints on debt reduction share repurchases and strategic investments. The static free cash flow outlook also raises questions about the sustainability of the current capital allocation strategy which balances buybacks with reinvestment needs. Should operating cash generation weaken the firm might need to prioritize debt repayment over shareholder returns or delay planned technology upgrades. Such a scenario could limit the upside potential of the growth initiatives that management has highlighted.